Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB01224,Quetiapine
,27803466,absolute oral bioavailability,"In addition, NQTP had a greater absolute oral bioavailability compared to QTP (15.6% vs. 0.63%, respectively).",Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803466/),%,15.6,22130,DB01224,Quetiapine
,27803466,absolute oral bioavailability,"In addition, NQTP had a greater absolute oral bioavailability compared to QTP (15.6% vs. 0.63%, respectively).",Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803466/),%,0.63,22131,DB01224,Quetiapine
,23739636,serum concentrations,"Median serum concentrations of Q and NQ were 46 ng/mL (25th to 75th percentile 20-91 ng/mL) and 59 ng/mL (25th to 75th percentile 26-133 ng/mL), respectively.",Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739636/),[ng] / [ml],46,25261,DB01224,Quetiapine
,23739636,serum concentrations,"Median serum concentrations of Q and NQ were 46 ng/mL (25th to 75th percentile 20-91 ng/mL) and 59 ng/mL (25th to 75th percentile 26-133 ng/mL), respectively.",Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739636/),[ng] / [ml],59,25262,DB01224,Quetiapine
,23739636,Concentrations per dose,Concentrations per dose ranged from 0.10 to 0.58 ng·ml·mg for Q and from 0.17 to 0.59 ng·ml·mg for NQ.,Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739636/),mg·ml·ng,0.10 to 0.58,25263,DB01224,Quetiapine
,23739636,Concentrations per dose,Concentrations per dose ranged from 0.10 to 0.58 ng·ml·mg for Q and from 0.17 to 0.59 ng·ml·mg for NQ.,Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739636/),mg·ml·ng,0.17 to 0.59,25264,DB01224,Quetiapine
,18294091,t(max) (time to maximum plasma concentration),"Quetiapine was rapidly absorbed after 200-mg and 400-mg doses in pediatric patients [median t(max) (time to maximum plasma concentration) 1.5 hours, both doses] and adult patients (median t(max) 1.0 hour and 1.2 hours, respectively).","Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294091/),h,1.5,36571,DB01224,Quetiapine
,18294091,t(max),"Quetiapine was rapidly absorbed after 200-mg and 400-mg doses in pediatric patients [median t(max) (time to maximum plasma concentration) 1.5 hours, both doses] and adult patients (median t(max) 1.0 hour and 1.2 hours, respectively).","Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294091/),h,1.0,36572,DB01224,Quetiapine
,18294091,t(max),"Quetiapine was rapidly absorbed after 200-mg and 400-mg doses in pediatric patients [median t(max) (time to maximum plasma concentration) 1.5 hours, both doses] and adult patients (median t(max) 1.0 hour and 1.2 hours, respectively).","Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294091/),h,1.2,36573,DB01224,Quetiapine
,18294091,t(1/2) (terminal elimination half-life),The mean quetiapine t(1/2) (terminal elimination half-life) was approximately 6 hours for pediatric and 5 hours for adult patients.,"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294091/),h,6,36574,DB01224,Quetiapine
,18294091,t(1/2) (terminal elimination half-life),The mean quetiapine t(1/2) (terminal elimination half-life) was approximately 6 hours for pediatric and 5 hours for adult patients.,"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294091/),h,5,36575,DB01224,Quetiapine
,26873228,area under the plasma concentration-time curve from time zero to infinity (AUC∞),"Rectal quetiapine produced an area under the plasma concentration-time curve from time zero to infinity (AUC∞) approximately 90 % greater than that produced by an equal (milligram per milligram) dose of oral quetiapine (15,333 ng/mL versus 8118.8 ng/mL, p = 0.005).","A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873228/),[ng] / [ml],"15,333",41760,DB01224,Quetiapine
,26873228,area under the plasma concentration-time curve from time zero to infinity (AUC∞),"Rectal quetiapine produced an area under the plasma concentration-time curve from time zero to infinity (AUC∞) approximately 90 % greater than that produced by an equal (milligram per milligram) dose of oral quetiapine (15,333 ng/mL versus 8118.8 ng/mL, p = 0.005).","A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873228/),[ng] / [ml],8118.8,41761,DB01224,Quetiapine
,28545354,percentage drug release,The percentage drug release after 24 h was found to be 95.81%.,Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28545354/),%,95.81,50014,DB01224,Quetiapine
,32012278,oral clearance,"A maximum decrease of 58% was predicted during trimester 2, and being associated with a statistically significant decrease in oral clearance at gestation week 25, 204 l/h ± 100.8 l/h compared with non-pregnant subjects, 121.9 l/h ± 51.8 l/h.",Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012278/),[l] / [h],204,50520,DB01224,Quetiapine
,32012278,oral clearance,"A maximum decrease of 58% was predicted during trimester 2, and being associated with a statistically significant decrease in oral clearance at gestation week 25, 204 l/h ± 100.8 l/h compared with non-pregnant subjects, 121.9 l/h ± 51.8 l/h.",Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012278/),[l] / [h],121.9,50521,DB01224,Quetiapine
excess of,32012278,trough concentration,A dosing optimisation strategy identified that dose increases to 500-700 mg twice daily would result in 32-55% of subjects possessing trough concentration in excess of 50 ng/ml.,Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012278/),[ng] / [ml],50,50522,DB01224,Quetiapine
,15000896,tmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,2.0,53468,DB01224,Quetiapine
,15000896,tmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,4.0,53469,DB01224,Quetiapine
,15000896,tmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,3.0,53470,DB01224,Quetiapine
,15000896,t1/2,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,7,53471,DB01224,Quetiapine
,15000896,t1/2,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,9.4,53472,DB01224,Quetiapine
,15000896,t1/2,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),h,8,53473,DB01224,Quetiapine
,15000896,Cmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],678,53474,DB01224,Quetiapine
,15000896,Cmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],19,53475,DB01224,Quetiapine
,15000896,Cmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],451,53476,DB01224,Quetiapine
,15000896,Cmax,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],58,53477,DB01224,Quetiapine
,15000896,Cmin,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],51,53478,DB01224,Quetiapine
,15000896,Cmin,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],3.3,53479,DB01224,Quetiapine
,15000896,Cmin,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],35,53480,DB01224,Quetiapine
,15000896,Cmin,"The main pharmacokinetic parameters of quetiapine, 7-hydroxy-N-dealkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine were as follows: tmax were 2.0 (0.3-5.0), 4.0 (1.5-6.0), 3.0 (0.5-5.0), and 3.0 (0.5-5.0) h respectively; t1/2 were (7+/-3), (9.4+/-2.7), (7+/-3), and (8+/-5) h, respectively; Cmax(SS) were (678+/-325), (19+/-5), (451+/-216), and (58+/-22) microg/L, respectively; Cmin(SS) were (51+/-68), (3.3+/-1.6), (35+/-36), and (5+/-4) microg/L, respectively; Cav(SS) were (295+/-144), (13+/-4), (209+/-71), and (28+/-9) micro/L, respectively; AUC(0-12)(SS) were (3,538+/-1 728), (153+/-44), (2,512+/-854), and (335+/-104) microg.h.L(-1), respectively; AUC(0-infinite)(SS) were (5,534+/-4 198), (287+/-107), (3,858+/-2 012), and (529+/-262) microg.h.L(-1), respectively; Ke were (0.11+/-0.03), (0.079+/-0.019), (0.11+/-0.03), and (0.103+/-0.028) h(-1), respectively; CL/F and V/F of quetiapine were (67+/-25) L.h(-1) and (672+/-394) L, respectively.",Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15000896/),[μg] / [l],5,53481,DB01224,Quetiapine
,32518042,apparent oral clearance,"The final population mean values of apparent oral clearance and apparent volume of distribution were 87.7 L/h and 277 L, respectively, and the interindividual %CVs were 32.6% and 75.0%, respectively.",Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518042/),[l] / [h],87.7,55328,DB01224,Quetiapine
,32518042,apparent volume of distribution,"The final population mean values of apparent oral clearance and apparent volume of distribution were 87.7 L/h and 277 L, respectively, and the interindividual %CVs were 32.6% and 75.0%, respectively.",Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518042/),l,277,55329,DB01224,Quetiapine
,25975812,apparent volume of distribution,"The typical apparent volume of distribution and elimination rate constant of quetiapine were 574 L and 0.12 h(-) (1) , respectively.","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),l,574,65450,DB01224,Quetiapine
,25975812,elimination rate constant,"The typical apparent volume of distribution and elimination rate constant of quetiapine were 574 L and 0.12 h(-) (1) , respectively.","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),(1)·h(-),0.12,65451,DB01224,Quetiapine
,25975812,population absorption rate constants,"The estimated population absorption rate constants were 1.46 and 0.10 h(-1) for quetiapine IR and XR, respectively.","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),1/[h],1.46,65452,DB01224,Quetiapine
,25975812,population absorption rate constants,"The estimated population absorption rate constants were 1.46 and 0.10 h(-1) for quetiapine IR and XR, respectively.","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),1/[h],0.10,65453,DB01224,Quetiapine
,25975812,steady-state AUC (AUCss ),"Simulation conducted with the final quetiapine population PK model predicted that the administration of a 200-mg twice-daily dose of quetiapine IR in Chinese patients would achieve a steady-state AUC (AUCss ) ± standard deviation of 3087 ± 1480 ng · h/mL, which is in close agreement with the reported value (3538 ± 1728 ng · h/mL).","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),[h·ng] / [ml],3087,65454,DB01224,Quetiapine
,25975812,steady-state AUC (AUCss ),"Simulation conducted with the final quetiapine population PK model predicted that the administration of a 200-mg twice-daily dose of quetiapine IR in Chinese patients would achieve a steady-state AUC (AUCss ) ± standard deviation of 3087 ± 1480 ng · h/mL, which is in close agreement with the reported value (3538 ± 1728 ng · h/mL).","Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975812/),[h·ng] / [ml],3538,65455,DB01224,Quetiapine
,24240480,peak plasma concentration,"The peak plasma concentration of quetiapine was 208.39 ng/ml for CYP3A5*1/*1, 243.46 ng/ml for CYP3A5*1/*3, and 332.94 ng/ml for CYP3A5*3/*3 (P=0.0118).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[ng] / [ml],208.39,67205,DB01224,Quetiapine
,24240480,peak plasma concentration,"The peak plasma concentration of quetiapine was 208.39 ng/ml for CYP3A5*1/*1, 243.46 ng/ml for CYP3A5*1/*3, and 332.94 ng/ml for CYP3A5*3/*3 (P=0.0118).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[ng] / [ml],243.46,67206,DB01224,Quetiapine
,24240480,peak plasma concentration,"The peak plasma concentration of quetiapine was 208.39 ng/ml for CYP3A5*1/*1, 243.46 ng/ml for CYP3A5*1/*3, and 332.94 ng/ml for CYP3A5*3/*3 (P=0.0118).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[ng] / [ml],332.94,67207,DB01224,Quetiapine
,24240480,AUC(inf) (area under the time vs. concentration curve from 0 to infinity),"The mean AUC(inf) (area under the time vs. concentration curve from 0 to infinity) value was 627.3, 712.77, and 1045.29 ng h/ml, respectively (P=0.0017).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[h·ng] / [ml],627.3,67208,DB01224,Quetiapine
,24240480,AUC(inf) (area under the time vs. concentration curve from 0 to infinity),"The mean AUC(inf) (area under the time vs. concentration curve from 0 to infinity) value was 627.3, 712.77, and 1045.29 ng h/ml, respectively (P=0.0017).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[h·ng] / [ml],712.77,67209,DB01224,Quetiapine
,24240480,AUC(inf) (area under the time vs. concentration curve from 0 to infinity),"The mean AUC(inf) (area under the time vs. concentration curve from 0 to infinity) value was 627.3, 712.77, and 1045.29 ng h/ml, respectively (P=0.0017).",Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240480/),[h·ng] / [ml],1045.29,67210,DB01224,Quetiapine
,18793579,Seroquel,Seroquel were 886.60 +/- 356.50 vs.,Bioequivalence study of a generic quetiapine in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793579/),,886.60,67214,DB01224,Quetiapine
,18793579,Time to reach Cmax (tmax),"Time to reach Cmax (tmax) of Quantia 200 and Seroquel were 1.08 +/- 0.778 and 1.10 +/- 0.79 h, respectively, and thus not significantly different.",Bioequivalence study of a generic quetiapine in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793579/),h,1.08,67215,DB01224,Quetiapine
,18793579,Time to reach Cmax (tmax),"Time to reach Cmax (tmax) of Quantia 200 and Seroquel were 1.08 +/- 0.778 and 1.10 +/- 0.79 h, respectively, and thus not significantly different.",Bioequivalence study of a generic quetiapine in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793579/),h,1.10,67216,DB01224,Quetiapine
,10945320,terminal elimination half-life,Decline in serum quetiapine concentration followed a biexponential pattern with a terminal elimination half-life of 22 hours.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,22,71498,DB01224,Quetiapine
,10945320,terminal elimination half-life,Elevated serum concentrations associated with this overdose remained above the limit of detection long enough to document a terminal elimination half-life of 22 hours in this patient.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,22,71499,DB01224,Quetiapine
,10945320,half-life,This is much more consistent with previously noted duration of clinical effects and detectable serum concentrations after overdose than the published half-life of 6 hours.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,6,71500,DB01224,Quetiapine
,16832315,elimination half-life,"The elimination half-life of the drug averaged 3.9 and 2.9 hours and total body clearance averaged 3.5 and 3.0 L/hr/kg after study weeks 2 and 8, respectively.","Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832315/),h,3.9,80228,DB01224,Quetiapine
,16832315,elimination half-life,"The elimination half-life of the drug averaged 3.9 and 2.9 hours and total body clearance averaged 3.5 and 3.0 L/hr/kg after study weeks 2 and 8, respectively.","Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832315/),h,2.9,80229,DB01224,Quetiapine
,16832315,total body clearance,"The elimination half-life of the drug averaged 3.9 and 2.9 hours and total body clearance averaged 3.5 and 3.0 L/hr/kg after study weeks 2 and 8, respectively.","Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832315/),[l] / [h·kg],3.5,80230,DB01224,Quetiapine
,16832315,total body clearance,"The elimination half-life of the drug averaged 3.9 and 2.9 hours and total body clearance averaged 3.5 and 3.0 L/hr/kg after study weeks 2 and 8, respectively.","Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832315/),[l] / [h·kg],3.0,80231,DB01224,Quetiapine
,16421458,concentration/dose (C/D) ratio,"In females, the concentration/dose (C/D) ratio was 35.4% higher than in males (adjusted mean 0.144 ng/ml/mg for males versus 0.195 ng/ml/mg for females, respectively; P = 0.035).","Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16421458/),[ng] / [mg·ml],0.144,85590,DB01224,Quetiapine
,16421458,concentration/dose (C/D) ratio,"In females, the concentration/dose (C/D) ratio was 35.4% higher than in males (adjusted mean 0.144 ng/ml/mg for males versus 0.195 ng/ml/mg for females, respectively; P = 0.035).","Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16421458/),[ng] / [mg·ml],0.195,85591,DB01224,Quetiapine
,22569350,Cmax,The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002).,Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22569350/),[ng] / [ml],776.9,87628,DB01224,Quetiapine
,22569350,Cmax,The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002).,Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22569350/),[ng] / [ml],1452.3,87629,DB01224,Quetiapine
,22569350,oral clearance,The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03).,Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22569350/),[l] / [h],123.3,87630,DB01224,Quetiapine
,22569350,oral clearance,The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03).,Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22569350/),[l] / [h],60.3,87631,DB01224,Quetiapine
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB01224,Quetiapine
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB01224,Quetiapine
,15018785,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (2.0 mm x 125 mm, 3 microm, Germany) column, using water (formic acid: 2.70 mmol/l, ammonium acetate: 10 mmol/l)-acetonitrile (53:47) as mobile phase, with a flow-rate of 0.16 ml/min.","Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),[ml] / [min],0.16,91882,DB01224,Quetiapine
above,15018785,extraction recoveries,The average extraction recoveries for all the four analysts were at least above 80%.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,80,91883,DB01224,Quetiapine
higher,15018785,recoveries,The methodology recoveries were higher than 91% for the analysts.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,91,91884,DB01224,Quetiapine
,29912789,milk/plasma drug concentration ratio,"The mean milk/plasma drug concentration ratio at 2-hour postdose was 0.47 (SD, 0.50; range, 0.13-1.67).",Quetiapine Excretion Into Human Breast Milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29912789/),,0.47,98589,DB01224,Quetiapine
,29912789,milk concentration,"The mean milk concentration of each patient was 5.7 ng/mL (SD, 4.5; range, 1.4-13.9 ng/mL).",Quetiapine Excretion Into Human Breast Milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29912789/),[ng] / [ml],5.7,98590,DB01224,Quetiapine
,12562141,terminal half-life,"In humans, quetiapine exhibits linear pharmacokinetics with a mean terminal half-life of 7 hours.","Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562141/),h,7,99732,DB01224,Quetiapine
,9497016,plasma half-life,Quetiapine (Seroquel) is a novel antipsychotic with an atypical profile in animal models and a relatively short plasma half-life of 2.5 5 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2.5,114312,DB01224,Quetiapine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2,114313,DB01224,Quetiapine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),%,44,114314,DB01224,Quetiapine
,9497016,terminal plasma half-life,The terminal plasma half-life of quetiapine was 5.3 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,5.3,114315,DB01224,Quetiapine
,9497016,occupancy half-life,"Our data shows that quetiapine has a relatively low affinity for dopamine D2 receptors, with an occupancy half-life (10 h), which was about twice as long as that for plasma.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,10,114316,DB01224,Quetiapine
,9497016,receptor occupancy half-life,"A more prolonged blockade of the serotonin 5HT2 receptors was found in the frontal cortex, with receptor occupancy half-life of 27 h.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,27,114317,DB01224,Quetiapine
,17410121,half-life,The median and interquartile range of the half-life for individual patients was 6.6 h (4.9-8.4 h).,Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410121/),h,6.6,115640,DB01224,Quetiapine
,22345050,run time,"Chromatography was performed isocratically on a C(18), 5 µm analytical column and the run time was 1.8 min.","A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345050/),min,1.8,115889,DB01224,Quetiapine
,26643946,percentage diffusion,Liposomal dispersion has been proved superior with greater percentage diffusion of 32.61 ± 1.70 and very high permeability with a coefficient value of 4.1334 ± 0.7321 (× 10 (-) (5 )cm/s).,Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643946/),,32.61,125863,DB01224,Quetiapine
,26643946,coefficient,Liposomal dispersion has been proved superior with greater percentage diffusion of 32.61 ± 1.70 and very high permeability with a coefficient value of 4.1334 ± 0.7321 (× 10 (-) (5 )cm/s).,Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643946/),(,4.1334,125864,DB01224,Quetiapine
,23623924,retention times,"The retention times were 2.12, 2.24, 2.12 and 2.19min for quetiapine, norquetiapine and their respective stable labeled internal standards, respectively.",Development and validation of a sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of quetiapine and its active metabolite norquetiapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23623924/),min,2.12,128361,DB01224,Quetiapine
,23623924,retention times,"The retention times were 2.12, 2.24, 2.12 and 2.19min for quetiapine, norquetiapine and their respective stable labeled internal standards, respectively.",Development and validation of a sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of quetiapine and its active metabolite norquetiapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23623924/),min,2.24,128362,DB01224,Quetiapine
,23623924,retention times,"The retention times were 2.12, 2.24, 2.12 and 2.19min for quetiapine, norquetiapine and their respective stable labeled internal standards, respectively.",Development and validation of a sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of quetiapine and its active metabolite norquetiapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23623924/),min,2.19,128363,DB01224,Quetiapine
,23623924,Cycle time,Cycle time was 4min.,Development and validation of a sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of quetiapine and its active metabolite norquetiapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23623924/),min,4,128364,DB01224,Quetiapine
,24115903,half-life,"An antipsychotic drug, quetiapine fumarate has a short half-life of 6 h and administered multiple times per day.",Development of sustained release antipsychotic tablets using novel polysaccharide isolated from Delonix regia seeds and its pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115903/),h,6,132095,DB01224,Quetiapine
,21704238,AUC(0-36),"Arithmetic mean (SD) of AUC(0-36), AUC(0-∞), C(max), and T(max) were 3279 (1169) ng/mL/h, 3731 (1332) ng/mL/h, 341.5 (108.3) ng/mL, and (median [range]) 5.0 (1.5-12.0) hours, respectively, for the test formulation and 3528 (1308) ng/mL/h, 3546 (1350) ng/mL/h, 365.9 (136.4) ng/mL, and (median [range]) 5.0 (2.5-10.0) hours, respectively, for the reference formulation.","Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704238/),[ng] / [h·ml],3279,136954,DB01224,Quetiapine
,21704238,AUC(0-∞),"Arithmetic mean (SD) of AUC(0-36), AUC(0-∞), C(max), and T(max) were 3279 (1169) ng/mL/h, 3731 (1332) ng/mL/h, 341.5 (108.3) ng/mL, and (median [range]) 5.0 (1.5-12.0) hours, respectively, for the test formulation and 3528 (1308) ng/mL/h, 3546 (1350) ng/mL/h, 365.9 (136.4) ng/mL, and (median [range]) 5.0 (2.5-10.0) hours, respectively, for the reference formulation.","Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704238/),[ng] / [h·ml],3731,136955,DB01224,Quetiapine
,21704238,C(max),"Arithmetic mean (SD) of AUC(0-36), AUC(0-∞), C(max), and T(max) were 3279 (1169) ng/mL/h, 3731 (1332) ng/mL/h, 341.5 (108.3) ng/mL, and (median [range]) 5.0 (1.5-12.0) hours, respectively, for the test formulation and 3528 (1308) ng/mL/h, 3546 (1350) ng/mL/h, 365.9 (136.4) ng/mL, and (median [range]) 5.0 (2.5-10.0) hours, respectively, for the reference formulation.","Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704238/),[ng] / [h·ml],3731,136956,DB01224,Quetiapine
,21704238,T(max),"Arithmetic mean (SD) of AUC(0-36), AUC(0-∞), C(max), and T(max) were 3279 (1169) ng/mL/h, 3731 (1332) ng/mL/h, 341.5 (108.3) ng/mL, and (median [range]) 5.0 (1.5-12.0) hours, respectively, for the test formulation and 3528 (1308) ng/mL/h, 3546 (1350) ng/mL/h, 365.9 (136.4) ng/mL, and (median [range]) 5.0 (2.5-10.0) hours, respectively, for the reference formulation.","Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704238/),h,5.0,136957,DB01224,Quetiapine
,27443660,AUC<sub>τ</sub>,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[h·ng] / [ml],"7,161.18",140218,DB01224,Quetiapine
,27443660,AUC<sub>τ</sub>,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[h·ng] / [ml],"7,184.27",140219,DB01224,Quetiapine
,27443660,C<sub>max</sub>,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[ng] / [ml],595.61,140220,DB01224,Quetiapine
,27443660,C<sub>max</sub>,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[ng] / [ml],597.06,140221,DB01224,Quetiapine
,27443660,C<sub>min<,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[ng] / [ml],119.47,140222,DB01224,Quetiapine
,27443660,C<sub>min<,"Arithmetic mean (SD) for AUC<sub>τ</sub> were 7,161.18 (3,687.10) ng×h/mL and 7,184.27 (3,304.29) ng×h/mL, C<sub>max</sub> were 595.61 (345.98) ng/mL and 597.06 (253.67) ng/mL, and C<sub>min</sub> were 119.47 (84.24) ng/mL and 124.22 (137.68) ng/mL, respectively, for the test and reference.",Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions . ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443660/),[ng] / [ml],124.22,140223,DB01224,Quetiapine
,12444812,peak D(2) occupancy,"Quetiapine administration led to a mean peak D(2) occupancy of 62% +/- 10% 2 hours postdose, which declined to 14% +/- 8% approximately 20 hours postdose.",Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12444812/),%,62,146182,DB01224,Quetiapine
,12444812,peak D(2) occupancy,"Quetiapine administration led to a mean peak D(2) occupancy of 62% +/- 10% 2 hours postdose, which declined to 14% +/- 8% approximately 20 hours postdose.",Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12444812/),%,14,146183,DB01224,Quetiapine
,18948162,Maximum plasma concentration at steady state (C(max)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),[ng] / [ml],495.3,148511,DB01224,Quetiapine
,18948162,Maximum plasma concentration at steady state (C(max)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),[ng] / [ml],568.1,148512,DB01224,Quetiapine
,18948162,time to reach C(max) (t(max)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),h,5,148513,DB01224,Quetiapine
,18948162,time to reach C(max) (t(max)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),h,2,148514,DB01224,Quetiapine
,18948162,concentration at the end of 24 h dosing interval (C(min)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),[ng] / [ml],95.3,148515,DB01224,Quetiapine
,18948162,concentration at the end of 24 h dosing interval (C(min)),"Maximum plasma concentration at steady state (C(max)) was approximately 13% lower for quetiapine XR than for quetiapine IR (495.3 versus 568.1 ng/mL), time to reach C(max) (t(max)) was 5 h versus 2 h and mean concentration at the end of 24 h dosing interval (C(min)) was 95.3 versus 96.5 ng/mL, respectively.",Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948162/),[ng] / [ml],96.5,148516,DB01224,Quetiapine
,18641548,half life,The initially observed rapid decline of the plasma concentrations of quetiapine could be simulated by first-order kinetics (half life = 4.1 hr) and can most probably be explained by rapid distribution into tissues.,Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641548/),h,4.1,150805,DB01224,Quetiapine
,32723273,oral bioavailability,"QF, an anti-psychotic drug, has an oral bioavailability of 9% due to hepatic first- pass metabolism necessitating the use of high doses.","Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32723273/),%,9,151539,DB01224,Quetiapine
,32723273,%EE,"The optimized formulation showed a %EE of 77.21%, PS of 140.2 nm and surface charge of - 19.9mV.","Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32723273/),%,77.21,151540,DB01224,Quetiapine
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],392,156842,DB01224,Quetiapine
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],1323,156843,DB01224,Quetiapine
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],27,156844,DB01224,Quetiapine
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],16,156845,DB01224,Quetiapine
,24385309,metabolite to parent ratio,N-desalkyl quetiapine was formed from quetiapine with an approximate metabolite to parent ratio of 0.5 across the three dose groups.,Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),,0.5,161737,DB01224,Quetiapine
,24385309,elimination half-life (t ½),The geometric mean elimination half-life (t ½) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine).,Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),h,7,161738,DB01224,Quetiapine
,24385309,elimination half-life (t ½),The geometric mean elimination half-life (t ½) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine).,Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),h,18,161739,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],467,161740,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],740,161741,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],"1,126",161742,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],138,161743,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],262,161744,DB01224,Quetiapine
,24385309,"maximum plasma concentrations (C max) at steady state (C max,ss)","The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[ng] / [ml],426,161745,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"5,094",161746,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"7,685",161747,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"13,237",161748,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"2,284",161749,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"4,341",161750,DB01224,Quetiapine
,24385309,area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss),"The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively.",Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385309/),[h·ng] / [ml],"7,216",161751,DB01224,Quetiapine
,21383647,C/D ratio,The 5-95 percentiles of the C/D ratio ranged 15-fold (0.14-2.1 nmol/L/mg) for quetiapine and fivefold (0.44-2.1 nmol/L/mg) for N-desalkylquetiapine.,Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383647/),[nM] / [l·mg],0.14-2.1,173096,DB01224,Quetiapine
,21383647,C/D ratio,The 5-95 percentiles of the C/D ratio ranged 15-fold (0.14-2.1 nmol/L/mg) for quetiapine and fivefold (0.44-2.1 nmol/L/mg) for N-desalkylquetiapine.,Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383647/),[nM] / [l·mg],0.44-2.1,173097,DB01224,Quetiapine
,16628129,lag time,The blood concentration ranged from 1.1 to 8.8 mg/L with a lag time of 1 to 26.2 hours between time of ingestion and blood sampling at the emergency ward.,Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628129/),h,1 to 26.2,173973,DB01224,Quetiapine
<,32218187,steady state recovery time,"Plasma therapeutic concentration after treatment cessation was maintained for <24 h in 48% and 29.6% of patients, and a steady state recovery time of <48 h was achieved in 51% and 13.4% of patients on the IR and XR formulations, respectively.",Changing the Drug Delivery System: Does It Add to Non-Compliance Ramifications Control? A Simulation Study on the Pharmacokinetics and Pharmacodynamics of Atypical Antipsychotic Drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32218187/),h,48,174093,DB01224,Quetiapine
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,13.7,198581,DB01224,Quetiapine
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.5,198582,DB01224,Quetiapine
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.2,198583,DB01224,Quetiapine
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,6.9,198584,DB01224,Quetiapine
,22077248,half-life,In 13 cases quetiapine was analysed quantitatively in serum with a relevantly prolonged half-life (16 ± 12 h) and a median peak serum concentration of 3074 ng/mL.,Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077248/),h,16,199504,DB01224,Quetiapine
,22077248,peak serum concentration,In 13 cases quetiapine was analysed quantitatively in serum with a relevantly prolonged half-life (16 ± 12 h) and a median peak serum concentration of 3074 ng/mL.,Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077248/),[ng] / [ml],3074,199505,DB01224,Quetiapine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201024,DB01224,Quetiapine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201025,DB01224,Quetiapine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201026,DB01224,Quetiapine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201027,DB01224,Quetiapine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,74,201028,DB01224,Quetiapine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,57,201029,DB01224,Quetiapine
,18308793,D,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202598,DB01224,Quetiapine
,18308793,RO,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202599,DB01224,Quetiapine
,18308793,C(P),"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),[ng] / [ml],9.4-60.5,202600,DB01224,Quetiapine
,29649903,concentration (Cmax),"In-vivo studies contributed significantly higher plasma QTP-F concentration (Cmax), time for maximum plasma concentration (Tmax), area under the curve (AUC0-inf) and half-life (t1/2) as 18.32 ± 0.50 µg/ml, 8.00 ± 0.01 hrs, 6021.2 ± 5.09 µg.hrs/ml and 10.06 ± 0.43 hrs, respectively, for test-hydrogels when compared to reference market brand (Qusel® 200 mg, Hilton Pharma, Karachi, Pakistan) QTP-F tablets.",Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649903/),[μg] / [ml],18.32,207830,DB01224,Quetiapine
,29649903,time for maximum plasma concentration (Tmax),"In-vivo studies contributed significantly higher plasma QTP-F concentration (Cmax), time for maximum plasma concentration (Tmax), area under the curve (AUC0-inf) and half-life (t1/2) as 18.32 ± 0.50 µg/ml, 8.00 ± 0.01 hrs, 6021.2 ± 5.09 µg.hrs/ml and 10.06 ± 0.43 hrs, respectively, for test-hydrogels when compared to reference market brand (Qusel® 200 mg, Hilton Pharma, Karachi, Pakistan) QTP-F tablets.",Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649903/),[h·μg] / [ml],6021.2,207831,DB01224,Quetiapine
,29649903,area under the curve (AUC0-inf),"In-vivo studies contributed significantly higher plasma QTP-F concentration (Cmax), time for maximum plasma concentration (Tmax), area under the curve (AUC0-inf) and half-life (t1/2) as 18.32 ± 0.50 µg/ml, 8.00 ± 0.01 hrs, 6021.2 ± 5.09 µg.hrs/ml and 10.06 ± 0.43 hrs, respectively, for test-hydrogels when compared to reference market brand (Qusel® 200 mg, Hilton Pharma, Karachi, Pakistan) QTP-F tablets.",Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649903/),h,8.00,207832,DB01224,Quetiapine
,29649903,area under the curve (AUC0-inf),"In-vivo studies contributed significantly higher plasma QTP-F concentration (Cmax), time for maximum plasma concentration (Tmax), area under the curve (AUC0-inf) and half-life (t1/2) as 18.32 ± 0.50 µg/ml, 8.00 ± 0.01 hrs, 6021.2 ± 5.09 µg.hrs/ml and 10.06 ± 0.43 hrs, respectively, for test-hydrogels when compared to reference market brand (Qusel® 200 mg, Hilton Pharma, Karachi, Pakistan) QTP-F tablets.",Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649903/),[h·μg] / [ml],6021.2,207833,DB01224,Quetiapine
,29649903,half-life (t1/2),"In-vivo studies contributed significantly higher plasma QTP-F concentration (Cmax), time for maximum plasma concentration (Tmax), area under the curve (AUC0-inf) and half-life (t1/2) as 18.32 ± 0.50 µg/ml, 8.00 ± 0.01 hrs, 6021.2 ± 5.09 µg.hrs/ml and 10.06 ± 0.43 hrs, respectively, for test-hydrogels when compared to reference market brand (Qusel® 200 mg, Hilton Pharma, Karachi, Pakistan) QTP-F tablets.",Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649903/),h,10.06,207834,DB01224,Quetiapine
,32623931,brain to plasma ratio,"The brain to plasma ratio of QTE increased upon QCN pre-treatment (2.6 vs 7.7), which could be attributed to P-glycoprotein inhibition at the blood-brain barrier by QCN.",Impact of quercetin on pharmacokinetics of quetiapine: insights from in-vivo studies in wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32623931/),,2.6,219622,DB01224,Quetiapine
,32623931,brain to plasma ratio,"The brain to plasma ratio of QTE increased upon QCN pre-treatment (2.6 vs 7.7), which could be attributed to P-glycoprotein inhibition at the blood-brain barrier by QCN.",Impact of quercetin on pharmacokinetics of quetiapine: insights from in-vivo studies in wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32623931/),,7.7,219623,DB01224,Quetiapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB01224,Quetiapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB01224,Quetiapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,384.1,233921,DB01224,Quetiapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,253.1,233922,DB01224,Quetiapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,327.0,233923,DB01224,Quetiapine
over,22337805,extraction recoveries,The extraction recoveries of quetiapine were over 90%.,Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),%,90,233924,DB01224,Quetiapine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,50,243487,DB01224,Quetiapine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,32,243488,DB01224,Quetiapine
,20201782,elimination half-life,The toxicokinetic data revealed a markedly prolonged elimination half-life for quetiapine (62.4 hours) and the relationship with antiretroviral therapy is discussed.,Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20201782/),h,62.4,250127,DB01224,Quetiapine
,16390352,plasma C(max),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],45 to 150,252117,DB01224,Quetiapine
,16390352,clearance (Cl/F),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],138 to 22,252118,DB01224,Quetiapine
,16390352,plasma C(max),"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],1042 to 205,252119,DB01224,Quetiapine
,16390352,clearance,"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],65 to 483,252120,DB01224,Quetiapine
,22794154,Tmax,"The Tmax and T1/2 for the test formulation were 2.26 and 10.92 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,2.26,258181,DB01224,Quetiapine
,22794154,T1/2,"The Tmax and T1/2 for the test formulation were 2.26 and 10.92 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,10.92,258182,DB01224,Quetiapine
,22794154,Tmax,"In addition, the Tmax and T1/2 for the reference formulation were 2.44 and 11.08 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,2.44,258183,DB01224,Quetiapine
,22794154,T1/2,"In addition, the Tmax and T1/2 for the reference formulation were 2.44 and 11.08 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,11.08,258184,DB01224,Quetiapine
,14704131,flow-rate,"The HPLC separation of the compounds was performed on a Kromasil C18, (5 microm, 4.6 mm.150 mm) column, using water (formic acid: 1.70 mmol/L, ammonium acetate: 5.8 mmol/L)-acetonitrile (65:35) as mobile phase, with a flow-rate of 0.95 mL/min.",Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704131/),[ml] / [min],0.95,261173,DB01224,Quetiapine
above,14704131,extraction recoveries,The average extraction recoveries for all the four samples were above 85 %.,Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704131/),%,85,261174,DB01224,Quetiapine
higher,14704131,recoveries,The methodology recoveries were much higher than 95 %.,Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704131/),%,95,261175,DB01224,Quetiapine
,19393840,C(max),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),[ng] / [ml],689.19,262093,DB01224,Quetiapine
,19393840,C(max),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),[ng] / [ml],381.70,262094,DB01224,Quetiapine
,19393840,AUC(0-11),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),[h·ng] / [ml],2835.89,262095,DB01224,Quetiapine
,19393840,AUC(0-11),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),[h·ng] / [ml],2515.21,262096,DB01224,Quetiapine
,19393840,T(max),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),h,2.0,262097,DB01224,Quetiapine
,19393840,T(max),"On day 5, the mean (95% CI) quetiapine C(max) for the IR and XR formulations was 689.19 (605.83-784.02) and 381.70 (341.40-426.76) ng/mL; the mean was AUC(0-11) was 2835.89 (2517.92-3194.02) and 2515.21 (2281.76--2772.55) ng . h/mL; and the median T(max) was 2.0 and 5.0 hours.","Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393840/),h,5.0,262098,DB01224,Quetiapine
,26018409,flow rate,"The separation was performed on a Venusil XBP PH column (5 µm, 2.0×100 mm) with an isocratic mobile phase consisted of methanol-water (containing 50 mM ammonium formate) (65:35, v/v) at a flow rate of 0.3 mL/min.",Pharmacokinetic study of isatin in dog plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26018409/),[ml] / [min],0.3,263420,DB01224,Quetiapine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,298.1,266332,DB01224,Quetiapine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,154.1,266333,DB01224,Quetiapine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,376.2,266334,DB01224,Quetiapine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,165.2,266335,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,9.4,273896,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,6.2,273897,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,1.7-26.8,273898,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,3.9,273899,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,3.8,273900,DB01224,Quetiapine
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,1.5-7.6,273901,DB01224,Quetiapine
